EXACT Therapeutics first half 2025 interim results
EXACT Therapeutics first half 2025 interim results
25 September, 2025: EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), a clinical stage precision health company utilising Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announces its interim results for the first half 2025.
The interim report for the first half year 2025 is also available on the company's website: www.exact-tx.com.
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: [email protected]
John M. Edminson
CFO EXACT Therapeutics
Email: [email protected]
About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound and microbubbles to enable targeted drug delivery in oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further information may be found here: www.exact-tx.com